TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8942005
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin injection using unbuffered regular insulin
Study: 8942005
Drug: Isophane insulin
Normalized name: Isophane insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isophane insulin injected at bedtime
Study: 1723684
Drug: Urinary trypsin
Normalized name: Urinary trypsin inhibitor 1
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary trypsin inhibitor for 3 days postoperatively
Study: 1723684
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no therapeutic agent)
Study: 1723684
Drug: Urinary trypsin
Normalized name: Urinary trypsin inhibitor 1
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary trypsin inhibitor
Study: 7041937
Drug: Bendrofluazide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (5 mg a day)
Study: 7041937
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of indapamide and bendrofluazide
Study: 29462248
Drug: Non-platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-platinum-based chemotherapy (NPBC)
Study: 18258988
Drug: Locoregional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapy based on pretreatment clinical extent of disease and pathologic extent after chemotherapy
Study: 9481995
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg/night)
Study: 9481995
Drug: Placebo (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (25 mg/night)
Study: 3371084
Drug: Frusemide/amiloride (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide/amiloride (40 mg frusemide plus 5 mg amiloride per tablet)
Study: 3371084
Drug: Bumetanide/potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide/potassium chloride (0.5 mg bumetanide plus 573 mg slow‐release potassium chloride per tablet)
Study: 30201040
Drug: Baby Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baby Triple P Positive Parenting Programme plus treatment as usual (TAU)
Study: 26816607
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day duloxetine
Study: 24331628
Drug: TACE combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE combined with iodine [131I] metuximab injection
Study: 24331628
Drug: TACE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE therapy alone (Control Group)
Study: 20147334
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (good PS)
Study: 20147334
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (poor PS)
Study: 16632815
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron (1 mg)
Study: 9793287
Drug: Fluconazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (50 mg daily for 14 days)
Study: 9793287
Drug: Itraconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (100 mg daily for 15 days)
Study: 2518679
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment (NGO, 18 mg)
Study: 6758932
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg tiapamil intravenously
Study: 30969142
Drug: Lower sodium
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower sodium chloride diet (6 g/d)
Study: 30969142
Drug: Higher sodium
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher sodium chloride diet (12 g/d)
Study: 29368069
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with red, 655-nm laser light, 150 mW, 2 J/cm2, on days 0, 3, 5, and 7
Study: 19546072
Drug: Trimetazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (60 mg/day orally for 2 weeks before surgery)
Study: 17635062
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic and fluid resuscitation (Control)
Study: 15726917
Drug: Estradiol (1
Normalized name: fluoroestradiol (18F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (1 mg oral)
Study: 12046257
Drug: Effervescent tablet
Normalized name: Pain Relief Effervescent Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent tablet (Calcium 500 mg Pharmavit)
Study: 12046257
Drug: Milk (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (250 ml enriched with milk calcium complex)
Study: 9468366
Drug: ZDV 200
Normalized name: ZDV
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZDV 200 mg three times daily plus p24‐VLP (500 microg) in intramuscular alum monthly
Study: 9468366
Drug: ZDV 200
Normalized name: ZDV
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZDV 200 mg three times daily plus intramuscular administration of alum adjuvant monthly
Study: 9468366
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules plus p24‐VLP (500 microg) in intramuscular alum monthly
Study: 7589843
Drug: Increased fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased fasting insulin (quartile 4, high)
Study: 7589843
Drug: Increased fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased fasting insulin and decreased delta I30/delta G30
Study: 2202010
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion for 12 hours during arteriography
Study: 2202010
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion during arteriography
Study: 28041700
Drug: Telmisartan 80mg
Normalized name: TELMISARTAN 80MG TAB
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 80mg once daily for six months
Study: 28041700
Drug: Enalapril 20mg
Normalized name: enalapril 20 MG
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril 20mg once daily for six months
Study: 21562072
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (wP, 80 mg/m(2)/week)
Study: 21562072
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel + carboplatin (wP + C, AUC 5 mg/ml/min every 4 weeks)
Study: 21562072
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel + topotecan (wP + wT, 3 mg/m(2)/week)
Study: 21562072
Drug: Control (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (monotherapy vs combination therapy)
Study: 11862589
Drug: Basiliximab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (40 mg, two 20 mg bolus injections on days 0 and 4)
Study: 11862589
Drug: Basiliximab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (40 mg)
Study: 10215945
Drug: Malmö Treatment
Normalized name: Salmo masoni flesh
DrugBank: Rainbow trout (DB15540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malmö Treatment Model protocol including immunoadsorption, cyclophosphamide (12-15 mg/kg bw intravenously for 2 days, then 2-3 mg/kg bw orally for 8-10 days), and intravenous gammaglobulin (0.4 g/kg bw daily for 5 days)
Study: 10215945
Drug: Malmö Treatment
Normalized name: Salmo masoni flesh
DrugBank: Rainbow trout (DB15540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malmö Treatment Model protocol
Study: 7611753
Drug: AO‐90 amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: AO‐90 amino acid solution (methionine-depleting TPN) with 5‐FU and MMC
Study: 7611753
Drug: Amiparen (commercial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiparen (commercial methionine and cysteine containing amino acid solution) with 5‐FU and MMC
Study: 7611753
Drug: AO‐90 amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: AO‐90 amino acid solution (methionine-depleting TPN) with 5‐FU for 7 days
Study: 7611753
Drug: Amiparen (commercial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiparen (commercial methionine and cysteine containing amino acid solution) with 5‐FU for 7 days
Study: 80632
Drug: Ancrod (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ancrod (5 daily subcutaneous injections)
Study: 31999405
Drug: Hijamat (wet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hijamat (wet cupping therapy) plus standard lifestyle modification
Study: 22971205
Drug: Pharmacist-led pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led pharmaceutical care intervention program
Study: 15125352
Drug: Esmolol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 150 mcg/kg
Study: 15125352
Drug: Nicardipine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 15 mcg/kg
Study: 15125352
Drug: Lidocaine 1
Normalized name: lidocaine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1 mg/kg
Study: 9928562
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy (CT) and reduced-dose radiation therapy (RT)
Study: 9928562
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy (CT) and full-dose radiation therapy (RT)
Study: 9928562
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy starting with chemotherapy (CT)
Study: 9928562
Drug: Initiating radiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initiating radiation therapy (RT) sooner
Study: 9928562
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment regimens delivering CT in a short time period (Adriamycin and Cytoxan in four 3-week cycles)
Study: 3300561
Drug: Regimen B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B: metoclopramide and droperidol (2.5 mg i.v. every 8 h X 3)
Study: 30032828
Drug: Escalated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated therapy (B) with radiation dose up to 84 Gy
Study: 30032828
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (A) with radiation dose of 68 Gy
Study: 25316134
Drug: Biophysical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biophysical therapy (Med Select 729)
Study: 16447669
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group given 20 mL of Shenmai Injectio intravenously for 6 days
Study: 8248611
Drug: Propofol (1-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1-1.5 mg/kg) administered before retrobulbar anesthesia
Study: 2935243
Drug: Hepatic resection
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic resection plus continuous hepatic artery infusion (CHAI) of fluorodeoxyuridine (FUDR)
Study: 22575076
Drug: Baker's yeast
Normalized name: Baker's yeast proteinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baker's yeast β-glucan (250 mg/d)
Study: 21910332
Drug: Needling +
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needling + Fluoxetine
Study: 17391911
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for fear of flying, 8 sessions
Study: 12679475
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (n=8)
Study: 12679475
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n=8)
Study: 8919832
Drug: Ketorolac 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.4 mg/kg administered 10 min before induction
Study: 8919832
Drug: Ketorolac 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.4 mg/kg administered 5 min after decollement of nasal septum
Study: 6117988
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bunitrolol (Stresson)
Study: 6117988
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg bunitrolol (Stresson)
Study: 31642408
Drug: Neurological music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurological music therapy intervention for 3 months (AB group)
Study: 31642408
Drug: Neurological music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurological music therapy intervention for 3 months (BA group)
Study: 31396693
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) subcutaneous administration
Study: 28276192
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of medroxyprogesterone acetate (MPA) per day
Study: 28276192
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of medroxyprogesterone acetate (MPA) per day
Study: 20957399
Drug: Parecoxib 80
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 80 mg daily i.v.
Study: 20957399
Drug: Lornoxicam 16
Normalized name: Lornoxicam 16 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 16 mg daily i.v.
Study: 20957399
Drug: Diclofenac 150
Normalized name: diclofenac sodium 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 150 mg daily i.m.
Study: 18795893
Drug: Oral antioxidants
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antioxidants (vitamins C and E, and alpha‐lipoic acid)
Study: 18795893
Drug: Antioxidant administration
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant administration after exercise training
Study: 16970165
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg once a day for 8 weeks
Study: 15137556
Drug: Music-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music-based exercise programme (daily physical exercises supported by music for 30 min/session for three months)
Study: 15137556
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily conversation for the same duration)
Study: 9314469
Drug: Vancomycin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (125 mg perorally four times daily for 7 days)
Study: 29294360
Drug: Ciclesonide 160
Normalized name: CICLESONIDE 160MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 160 μg once-daily
Study: 29294360
Drug: Glycopyrronium 44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium 44 μg once-daily
Study: 28872637
Drug: 24 healthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 healthy controls before and after 4 weeks of no treatment
Study: 17416954
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% proparacaine
Study: 12749495
Drug: Control (compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (compounds without ITNs)
Study: 8624657
Drug: 585-nm pulsed
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 585-nm pulsed dye laser treatment with 10-mm spot size and 3.0 J/cm2 fluence
Study: 8624657
Drug: 585-nm pulsed
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 585-nm pulsed dye laser treatment (all protocols)
Study: 8624657
Drug: 585-nm pulsed
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 585-nm pulsed dye laser treatment
Study: 23153036
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 20% essential oil of black pepper in aloe vera gel
Study: 19238088
Drug: Venlafaxine 225-375
Normalized name: venlafaxine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 225-375 mg/day
Study: 17989532
Drug: Allergen specific
Normalized name: Allergen specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen specific immunotherapy
Study: 16107993
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tenofovir disoproxil fumarate and full-dose didanosine
Study: 16107993
Drug: 1 or
Normalized name: G-1 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or neither of the agents (Control)
Study: 7657105
Drug: Cyclosporine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (5 mg.kg‐1.day‐1)
Study: 4923930
Drug: Medazepam 10
Normalized name: medazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medazepam 10 mg three times a day
Study: 4923930
Drug: Amylobarbitone 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amylobarbitone 60 mg three times a day
Study: 31978238
Drug: Life review
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life review (LR) therapy provided by family caregivers
Study: 25921522
Drug: Physician-directed patient
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-directed patient self-management therapeutic strategy based on left atrial pressure (LAP) measured twice daily by an implantable sensor
Study: 19786657
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with leucovorin and fluorouracil after six cycles of mFOLFOX7 (arm 1)
Study: 19786657
Drug: Chemotherapy-free interval
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-free interval (CFI) after six cycles of mFOLFOX7 (arm 2)
Study: 17482432
Drug: Quetiapine (50-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (50-400 mg/day)
Study: 17482432
Drug: Risperidone (0.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5-2 mg/day)
Study: 7965482
Drug: Rice-based ORS
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice-based ORS solution
Study: 7965482
Drug: Standard glucose-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glucose-based ORS solution
Study: 3655273
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g q.i.d. for 8 weeks
Study: 3655273
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg q.i.d. for 8 weeks
Study: 26311735
Drug: Cognitive-behavioral therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy-based techniques targeting grief, loss, and change
Study: 23252525
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg if weight ≥30 kg or 12 mg/kg if weight <30 kg) given intravenously every 2 weeks for 12 weeks
Study: 20517827
Drug: Magnesium (50
Normalized name: magnesium gluconate 27 mg magnesium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (50 mg/kg bolus followed by 10 mg/kg/h for 24 hours)
Study: 17991790
Drug: Added external
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Added external dead space (DS) of 200, 400, and 600 ml
Study: 16268802
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel (all doses)
Study: 12132061
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg + saline (FB)
Study: 12132061
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg + epinephrine 100 microg (FBE)
Study: 10072142
Drug: CGP 56697
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 56697 (4 x 4 tablets each containing 20 mg of artemether and 120 mg of benflumetol, given at 0, 8, 24, and 48 hr)
Study: 10072142
Drug: Mefloquine (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (three tablets of 250 mg at initial diagnosis, followed by two tablets of 250 mg at 8 hr)
Study: 7487854
Drug: Provision of
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provision of information (about oral health and dental treatment)
Study: 26934969
Drug: MOUTh intervention
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOUTh intervention (Managing Oral Hygiene Using Threat Reduction Strategies)
Study: 24201414
Drug: 60 ml/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml/h infusion of 30 mg nefopam
Study: 24201414
Drug: 120 ml/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 ml/h infusion of 30 mg nefopam
Study: 24201414
Drug: 180 ml/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 ml/h infusion of 30 mg nefopam
Study: 17805582
Drug: Dipyrone 500
Normalized name: dipyrone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 500 mg PO every 6 h
Study: 16607045
Drug: Basal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal treatment (aspirin 162 mg + cilostazol 200 mg/day)
Study: 16607045
Drug: ACEI (basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI (basal treatment + quinapril 10 mg or perindopril 4 mg/day)
Study: 16607045
Drug: ARB (basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (basal treatment + losartan 50 mg/day)
Study: 12943062
Drug: Broad-spectrum beta-lactam
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum beta-lactam antibiotics (Control)
Study: 1507816
Drug: Cordarone (intravenous)
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cordarone (intravenous)